Shares of Summit Therapeutics PLC (LON:SUMM) traded down 5.26% during trading on Tuesday, hitting GBX 135.00. The stock had a trading volume of 26,200 shares. The firm has a 50-day moving average price of GBX 101.94 and a 200 day moving average price of GBX 105.52. The company’s market capitalization is GBX 82.99 million. Summit Therapeutics PLC has a 52 week low of GBX 82.66 and a 52 week high of GBX 159.00.
About Summit Therapeutics PLC
Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.